Importing Korean Skincare Products into the US: A 2026 MoCRA Compliance Guide for Distributors and Brands

Korean skincare is one of the most attractive consumer import categories on the US market in 2026 — high consumer demand, strong duty-free treatment under KORUS, no Section 301 tariff exposure, and an exporter base that already understands Western compliance. But the rules changed materially when MoCRA enforcement took effect, and many distributors are still operating under the pre-2024 cosmetics regime. This guide walks through what importing Korean skincare products actually requires under the current US framework, from FDA facility registration to product listing, cosmetic-versus-drug classification, real landed costs, and the supplier diligence that separates clean operations from cargo holds.

The Korean skincare import opportunity in 2026

Korean skincare — K-beauty — has become one of the most resilient and fastest-growing categories in US cosmetic imports. American consumers buy Korean snail mucin serums, vitamin C ampoules, propolis essences, ceramide moisturizers, and cleansing oils at unprecedented volumes. Major US retailers (Sephora, Ulta, Target, Amazon, plus dozens of dedicated K-beauty platforms) all carry Korean lines. The market opportunity is large and still expanding, and the structural trade environment favors Korean origin.

For US importers, distributors, and brand owners, Korean skincare also offers something most other consumer goods categories do not in 2026: a meaningful tariff advantage. Korean-origin products are not subject to Section 301 tariffs (those apply to Chinese origin), and qualifying products receive duty-free treatment under the US-Korea Free Trade Agreement. The 25 percent tariff stack that hits Chinese skincare and cosmetics simply does not apply to Korean-origin equivalents.

The catch is that all of this opportunity sits behind a regulatory wall that got materially higher in 2024 when MoCRA took effect. Korean skincare products that ship into the US in 2026 without MoCRA-compliant facility registration and product listing can be held at the port, refused entry, or recalled from the market after they have already reached US shelves. The importers who are scaling profitably in this category have built MoCRA compliance into their operations as a default. The ones still relying on pre-MoCRA assumptions are losing inventory at customs.

MoCRA: the rule that changed everything

Before we get to process, you need to understand the regulatory shift. The Modernization of Cosmetics Regulation Act of 2022 — universally referred to as MoCRA — is the most significant update to US cosmetics regulation in over 80 years. It moved the FDA from a largely voluntary cosmetic registration regime into a mandatory framework with real enforcement teeth. Active enforcement of the facility registration and product listing requirements began July 1, 2024, and the regime continues to expand into 2026 and beyond.

What MoCRA actually requires

Five core requirements now apply to every cosmetic product sold in the United States, including imported Korean skincare:

• Facility registration. Every manufacturer, processor, and packer of cosmetics sold in the US must register with the FDA through the Cosmetics Direct platform using Form FDA 5066. Registration renews every two years.
• Product listing. Every cosmetic product marketed in the US must be listed in the FDA database using Form FDA 5067, with complete ingredient declarations. Listings must be updated annually.
• Responsible Person designation. Every product must have a named Responsible Person — the manufacturer, packer, or distributor whose name appears on the label.
• Safety substantiation. The Responsible Person must maintain adequate documentation that the product is safe under its intended conditions of use. No pre-market approval, but the documentation must exist and be producible on request.
• Adverse event reporting. Serious adverse events related to cosmetics must be reported to the FDA within 15 business days. Recordkeeping for adverse events runs at least six years.

Why MoCRA hits Korean skincare imports specifically

Korean manufacturers are generally well-prepared for MoCRA because Korea's own cosmetics regulatory framework under the Ministry of Food and Drug Safety has similar facility and product oversight. Many established Korean ODMs (original design manufacturers) and major brands had FDA-aligned compliance documentation in place before MoCRA enforcement began. The problem usually sits on the US side — importers who didn't realize they needed to register their suppliers and list every SKU before the first shipment.

Other FDA-regulated import categories follow similar logic. Our companion guide on importing face masks walks through the same FDA framework applied to PPE, including the post-Emergency-Use-Authorization reality that mirrors the post-MoCRA reality for cosmetics — older articles online are dangerously out of date, and the importers who scale are the ones operating under current rules rather than expired pandemic-era shortcuts.

The 9-step import process

Every commercial Korean skincare import follows the same fundamental sequence. The MoCRA layers stack on top of the standard customs and trade requirements.

From committed purchase order to delivered inventory in a US warehouse, plan for 30 to 55 days on a typical ocean shipment from Korea. Air freight cuts the timeline to 12 to 20 days total but costs significantly more per unit — usually worthwhile only for launch batches, replenishment of bestsellers, or shelf-life-sensitive products like fresh vitamin C ampoules.

Cosmetic vs drug: the classification trap

This is the single most common compliance failure in Korean skincare imports — and the one Korean ODMs often warn US importers about before the importers fully understand it. The FDA classifies a product based on its intended use, which is established by marketing claims, ingredients, and packaging language. Korean skincare marketing tends to be more aggressive with efficacy claims than US law permits, which means products that are legal cosmetics in Korea can become unapproved drugs the moment they reach US shelves.

The legal definitions

Cosmetic. A product intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance. Examples: moisturizer, cleanser, toner, eye cream, lipstick.

Drug. A product intended to diagnose, cure, mitigate, treat, or prevent disease, or intended to affect the structure or function of the body. Examples: sunscreen, anti-acne treatments, anti-dandruff shampoo, skin-lightening products containing hydroquinone.

Korean skincare claims that trigger drug classification

• SPF claims — any sunscreen function is a drug claim, regardless of product format
• Anti-acne efficacy — "treats acne," "clears acne," "kills acne-causing bacteria"
• Skin whitening / lightening — products marketed to reduce hyperpigmentation as a treatment
• Anti-wrinkle / anti-aging "treatment" — "treats wrinkles," "reverses signs of aging"
• Antibacterial / antimicrobial — any disease-prevention claim
• Healing or repair claims — "heals damaged skin," "repairs the skin barrier" in clinical language
• Hormonal or DNA claims — "stimulates collagen production," "alters cell function"

Cosmetic-safe versions of the same claims

The same product idea can usually be marketed legally in the US with softer cosmetic language. Instead of "treats wrinkles," use "minimizes the appearance of fine lines." Instead of "kills acne bacteria," use "for blemish-prone skin." Instead of "whitens skin," use "for a more radiant complexion." The line is whether you are claiming to change the body or just change appearance.

The Responsible Person designation

MoCRA introduced the concept of the "Responsible Person" — and this is one of the parts of the law that most catches new K-beauty importers off-guard. Every cosmetic product sold in the US must have a named Responsible Person on the label. The Responsible Person is the manufacturer, packer, or distributor whose name and address appear on the product, and they carry the legal accountability for MoCRA compliance.

Who can be the Responsible Person

For Korean skincare imports, the Responsible Person is almost always one of three parties:

• The Korean manufacturer. If the Korean brand sells under its own name in the US (Cosrx, Innisfree, Laneige operating direct), the Korean entity acts as Responsible Person, often with a US-registered subsidiary or agent.
• The US distributor or importer. If a US company imports a Korean ODM-produced product and rebrands or distributes under its own name, the US company is typically the Responsible Person.
• The US brand owner. If a US-owned brand contracts with Korean ODMs to manufacture products under the US brand's own labels (private label / white label), the US brand is the Responsible Person.

What the Responsible Person actually does

• Files Form FDA 5067 product listings for every product in the US market
• Maintains safety substantiation documentation for each product
• Receives and processes adverse event reports
• Reports serious adverse events to the FDA within 15 business days
• Maintains complete records for at least six years
• Ensures product labeling complies with US requirements
• Coordinates any product recall or market action

If you import Korean skincare and distribute under your own brand, you are almost certainly the Responsible Person. Many US importers don't realize this until after their first shipment arrives — and discover at that point that the legal accountability they assumed sat with the Korean manufacturer actually sits with them.

FDA facility registration and product listing

The two MoCRA filings that matter operationally are Form 5066 (facility registration) and Form 5067 (product listing). Both filings happen through the FDA's Cosmetics Direct portal, which the agency designed specifically for MoCRA.

Form FDA 5066: Facility Registration

This is filed by the manufacturer — for Korean skincare, that's the Korean facility making the product. The registration requires a FEI (FDA Establishment Identifier) number, full facility address, contact information, listing of all cosmetic product categories produced at the facility, and the responsible party's information. Facility registration must be renewed every two years.

Many established Korean ODMs have multiple FEI numbers covering different facilities, formulation labs, and packaging sites. For a US importer, the question to ask is not "do you have FDA registration" but "which facility is registered, what's its FEI, and what categories does that registration cover." Mismatches between registered facilities and the actual production location create import holds.

Form FDA 5067: Product Listing

This is filed by the Responsible Person — typically the US importer or brand owner. Each individual cosmetic product (each SKU) requires its own listing, with the manufacturer's FEI, the responsible party information, product category, complete ingredient list in International Nomenclature of Cosmetic Ingredients (INCI) format, and packaging details. Product listings must be updated annually if anything changes (new ingredients, reformulation, packaging changes) and renewed annually regardless.

The most common mistake is treating product listing as a one-time task. It is not. Every reformulation triggers a new listing requirement. Every SKU variant requires its own listing. Importers who launch a 12-SKU Korean skincare line need to maintain 12 separate active listings on a rolling basis.

FDA labeling requirements that hold shipments

Labels are the most common cause of FDA holds on Korean skincare imports. Korean labels are often beautifully designed but built for Korean and broader Asian markets — they frequently lack required US elements or include marketing claims that don't survive FDA scrutiny.

Required label elements for every cosmetic sold in the US

• Statement of identity — common or usual name of the product
• Net quantity of contents — in both metric and US customary units
• Name and place of business — of the Responsible Person (manufacturer, packer, or distributor)
• Ingredient declaration — in INCI format, in descending order of predominance
• Directions for safe use — if not obvious from the product type
• Warning statements — if applicable (eye contact, flammability, etc.)
• Country of origin — typically "Made in Korea" or "Product of Korea"
• English language — required; other languages may appear alongside

Common Korean label issues that trigger holds

• Net contents in milliliters only, missing US fluid ounce equivalent
• Ingredient list in Korean or other non-English language without English alongside
• Responsible Person address showing only the Korean manufacturer, not the US distributor when the US party is the Responsible Person
• Aggressive efficacy claims that cross into drug territory
• Ingredient names in trade names rather than INCI nomenclature
• Missing or incomplete allergen disclosures
• Inconsistent product names between label, packaging, and FDA listing

The cleanest approach for US importers is to work with the Korean supplier to develop a US-specific label version during the ordering process. The cost increase is minor compared to having shipments held at the port for label remediation. For volume importers, some Korean ODMs maintain dedicated US-spec lines that include all required US elements from the production run rather than as an overlay.

Tariffs, KORUS FTA, and duty math

This is where Korean skincare has a real structural advantage over Chinese-origin cosmetics. The US-Korea Free Trade Agreement (KORUS) provides duty-free treatment for most cosmetic products, and Korean origin is not subject to Section 301 tariffs.

Common HTS codes for Korean skincare

How to claim KORUS preferential treatment

• The product must be of Korean origin under the KORUS rules of origin
• A valid KORUS Certification of Origin must be obtained from the Korean exporter
• The certification must travel with the shipment documentation
• The importer must claim the preference on the customs entry (using the appropriate Special Program Indicator)
• Records supporting the preference claim must be retained for five years

Section 301: not your problem

The 25 percent Section 301 List 4A tariffs that hit many Chinese-origin cosmetics and beauty products do not apply to Korean origin. This is a meaningful structural advantage. A China-origin moisturizer of identical formulation would face Section 301 tariffs that immediately erase the cost advantage of Chinese manufacturing. The Korean equivalent ships duty-free and tariff-free. For deeper context on how this dynamic affects sourcing across categories, our companion guide on how to import from China to USA covers the China-specific tariff stack that Korean origin avoids.

Real 2026 landed cost breakdown

Numbers make the abstract concrete. Here is a worked example: a 20ft container of mid-tier Korean skincare (mixed SKUs — serums, moisturizers, sheet masks, declared value $40,000 FOB Busan) imported through the Port of Long Beach in 2026, with KORUS preferential treatment.

Compare that math to the equivalent shipment from China. A China-origin $40,000 cosmetic container would face the same MFN duty (0 percent under HTSUS general rates for skincare), but it would also carry the Section 301 List 4A 25 percent tariff of $10,000 on top. The Korean shipment lands at roughly $47,164. The Chinese equivalent would land at around $57,164 — about $10,000 more for the same product value, driven entirely by the Section 301 differential. That is the practical advantage of Korean origin in the current US trade environment.

The port operations side of this math — drayage, terminal handling, container freight station fees — is well-documented in our companion piece on Los Angeles import customs clearance, which walks through the specific LA/Long Beach port operations where most Asian-origin cosmetics arrive.

Vetting Korean skincare suppliers and ODMs

Korea has one of the deepest and most sophisticated cosmetic manufacturing ecosystems in the world. Major Korean ODMs — Kolmar Korea, Cosmax, Cosmecca Korea, Intercos Korea — produce for global beauty brands at industrial scale. Smaller specialized manufacturers handle indie K-beauty brands, private label launches, and innovative formulation work. The challenge for US importers is matching the right supplier to the right product strategy.

Three supplier types you'll encounter

Supplier due diligence checklist

• Verify FDA facility registration status and FEI number in the FDA database
• Confirm GMP compliance — most reputable Korean ODMs hold ISO 22716 or similar certifications
• Request ingredient documentation including INCI names and concentration ranges
• Review safety substantiation materials (especially for novel ingredients)
• Verify the supplier has experience exporting to MoCRA-compliant US markets
• Request samples for compatibility testing with your packaging and target market
• Audit factory capacity against your projected order volumes
• Confirm KORUS-qualifying status for preferential tariff treatment
• Review MOQ (minimum order quantity) requirements — they vary dramatically between large ODMs and indie manufacturers
• Establish contractual protections for facility registration changes, formulation modifications, and regulatory holds

For deeper context on managing international supplier relationships and the broader strategic considerations of an Asia-sourced consumer goods import operation, our companion piece on foreign trade consulting covers how outside expertise helps growing trade businesses build supplier programs that scale beyond a single product or single market.

Mistakes that get K-beauty shipments held or recalled

Most refused or delayed Korean skincare shipments trace back to the same handful of avoidable mistakes. Avoid these and you operate well ahead of most importers in this category.

• Skipping MoCRA registration. Without facility registration and product listing, the products are misbranded under US law. Customs holds are routine.
• Assuming the Korean supplier handled FDA. Sometimes they did; often they didn't, or did it incompletely. Verify in the FDA database before shipping.
• Misclassifying products with drug claims as cosmetics. SPF, anti-acne, and skin-whitening products are drugs under US law regardless of how they're marketed in Korea.
• Wrong Responsible Person on the label. The label must show the actual Responsible Person. If you're the US distributor and the label still shows the Korean manufacturer, you may be operating outside the MoCRA framework.
• Missing English ingredient declarations. Korean-only ingredient lists trigger label-based holds at the port.
• Lapsed product listings. Listings need annual renewal. Lapsed listings invalidate every subsequent shipment.
• Reformulation without listing update. A small ingredient change is supposed to trigger a listing update. Skipping it creates compliance exposure.
• No safety substantiation file. If FDA requests safety documentation and you cannot produce it, you have a problem regardless of how harmless the actual formulation is.
• Forgetting KORUS Certification of Origin. Without it, you pay any applicable MFN duty rate instead of getting duty-free treatment. Small but unnecessary cost.
• Single-source supplier dependency. If your one Korean facility's registration is suspended, you have no inventory. Build redundancy into critical SKUs.

"Korean skincare is one of the most attractive consumer import categories in the US right now. The structural tariff advantage is real, the consumer demand is real, and the supplier base is exceptional. The compliance work just has to actually get done."

Frequently asked questions

Read more on importing and global trade

If this guide was useful, here are related resources from our blog that go deeper on adjacent topics.